Ongoing analysis of data from the ODYSSEY OUTCOMES trial continues to shed light on the benefits of lowering elevated LDL-cholesterol (LDL-C) levels with the PCSK9 inhibitor alirocumab in patients at high risk of cardiovascular (CV) events.1-8 In this article, Professor Gerald Watts from the Royal Perth Hospital gives his impressions of the data. He also ...
PCSK9 inhibition in high risk ASCVD – insights into patient selection
21 Oct 2021
Sponsored by sanofi-aventis australia pty ltd